

Daftar Pustaka

- Ambari, E. *et al.* (2016) ‘Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regimen PVB in Cervical Cancer Stage IB-IIA’, *Indonesian Journal of Obstetrics and Gynecology*, (June 2014), pp. 156–160. doi: 10.32771/inajog.v1i3.357.
- American Cancer Society (2019) ‘Cervical Cancer Causes, Risk Factors, and Prevention Risk Factors’, *American Cancer Society*, p. 2.
- Andrijono and Indriyatmi, W. (2013) *Infeksi Human Papiloma Virus*. Jakarta: Fakultas Kedokteran Universitas Indonesia.
- Arbyn, M. *et al.* (2011) ‘Worldwide burden of cervical cancer in 2008’, *Annals of Oncology*, 22(12), pp. 2675–2686. doi: 10.1093/annonc/mdr015.
- Aster, V. . (2015) *Buku Ajar Patologi Robbins, Elseiver*.
- Badan Pengembangan dan Pembinaan Bahasa. (2016). KBBI Daring. Jakarta: Kementerian Pendidikan dan Kebudayaan Republik Indonesia
- Bhatla, N. *et al.* (2019) ‘Revised FIGO staging for carcinoma of the cervix uteri’, *International Journal of Gynecology and Obstetrics*, 145(1), pp. 129–135. doi: 10.1002/ijgo.12749.
- Byun, S. J. *et al.* (2013) ‘A comparison of outcomes between concurrent chemoradiotherapy and radiotherapy alone in cancer of the uterine cervix: A single institutional experience’, *European Journal of Gynaecological Oncology*, 34(5), pp. 402–408. doi: 10.1016/j.ijrobp.2012.07.1148.
- Carella, G. (2003) ‘Introduction to apoptosis in ophthalmology.’, *European journal of ophthalmology*, 13 Suppl 3, pp. 5–10. doi: 10.1177/112067210301303s02.
- Chen, H. *et al.* (2008) ‘Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study’, *Gynecologic Oncology*, 110(3), pp. 308–315. doi: 10.1016/j.ygyno.2008.05.026.
- Cibula, D. *et al.* (2018) ‘The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the

Management of Patients With Cervical Cancer’, *International Journal of Gynecological Cancer*, 28(4), pp. 641–655. doi: 10.1097/IGC.0000000000001216.

Colombo, N. *et al.* (2012) ‘Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up’, *Annals of Oncology*, 23(SUPPL. 7), pp. vii27–vii32. doi: 10.1093/annonc/mds268.

Dai, H., Meng, W. and Kaufmann, S. (2016) ‘BCL2 Family, Mitochondrial Apoptosis, and Beyond’, *Cancer Translational Medicine*, 2(1), p. 7. doi: 10.4103/2395-3977.177558.

Detre, S., Saccani Jotti, G. and Dowsett, M. (1995) ‘A “quickscore” method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas’, *Journal of Clinical Pathology*, 48(9), pp. 876–878. doi: 10.1136/jcp.48.9.876.

Di Saia, P.J., Creasman, W. (2012) *Clinical Gynecologic Oncology*. 8th edn. China: Elsevier.

ESGO (2017) ‘Cervical Cancer’, *The Lancet*, 328(8517), p. 1226. doi: 10.1016/S0140-6736(86)92243-9.

G. Martínez-Ruiz, Karla Vazquez-Santillan, G. V.-A. (2015) ‘Cervical cancer and apoptosis’. Available at: <https://www.semanticscholar.org/paper/Cervical-cancer-and-apoptosis-Mart%C3%ADnez-Ruiz-Vazquez-Santillan/c2f2be75d24d8ddf86e989b3eca822c21806417a#paper-header>.

Garrey, S. (2014) ‘Cervical Cancer in Uganda’, *Pulitzer Center on Crisis Reporting*. Available at: <http://pulitzercenter.org/projects/sub-saharan-africa-uganda-female-reproductive-health-cervical-cancer-HPV>.

Ghavami, S. *et al.* (2009) ‘Apoptosis and cancer: Mutations within *caspase* genes’, *Journal of Medical Genetics*, 46(8), pp. 497–510. doi: 10.1136/jmg.2009.066944.

Gupta, S. *et al.* (2018) ‘Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial’, *Journal of Clinical Oncology*, 36(16), pp. 1548–1555. doi: 10.1200/JCO.2017.75.9985.

Gupta, S. (2019) ‘Adjuvant chemotherapy in locally advanced cervical cancer: the ceiling

remains unbroken', 30(4), pp. 1–3.

- Hanahan, D. and Weinberg, R. A. (2011) 'Hallmarks of cancer: The next generation', *Cell*, 144(5), pp. 646–674. doi: 10.1016/j.cell.2011.02.013.
- Herzog, T. J. and Monk, B. J. (2007) 'Reducing the burden of glandular carcinomas of the uterine cervix', *American Journal of Obstetrics and Gynecology*, 197(6), pp. 566–571. doi: 10.1016/j.ajog.2007.08.055.
- Hoffman, B. L. et al (2012) *Williams Gynecology, Thr McGraw-Hill Companies*.
- Hoste, G., Vossaert, K. and Poppe, W. A. J. (2013) 'The Clinical Role of HPV Testing in Primary and Secondary Cervical Cancer Screening', *Obstetrics and Gynecology International*, 2013, pp. 1–7. doi: 10.1155/2013/610373.
- Hu, Q. et al. (2014) 'Elevated cleaved *caspase-3* is associated with shortened overall survival in several cancer types', *International Journal of Clinical and Experimental Pathology*, 7(8), pp. 5057–5070.
- Hu, T. et al. (2012) 'Matched-case comparison of neoadjuvant chemotherapy in patients with FIGO stage IB1-IIB cervical cancer to establish selection criteria', *European Journal of Cancer*, 48(15), pp. 2353–2360. doi: 10.1016/j.ejca.2012.03.015.
- Jin, X. J. et al. (2017) 'Negative correlation between X-linked inhibitors of apoptosis and second mitochondria-derived activator of *caspase* expression levels in cervical carcinoma and cervical intraepithelial neoplasia', *Oncology Letters*, 14(5), pp. 5340–5346. doi: 10.3892/ol.2017.6878.
- Kasamatsu, T. et al. (2009) 'Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation', *Gynecologic Oncology*, 114(1), pp. 69–74. doi: 10.1016/j.ygyno.2009.03.026.
- Katsumata, N. et al. (2013) 'Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: A Japan Clinical Oncology Group trial (JCOG 0102)', *British Journal of Cancer*, 108(10), pp. 1957–1963. doi: 10.1038/bjc.2013.179.

- Khalil, H. *et al.* (2012) ‘Caspase-3 Protects Stressed Organs against Cell Death’, *Molecular and Cellular Biology*, 32(22), pp. 4523–4533. doi: 10.1128/mcb.00774-12.
- Kumar, L. and Gupta, S. (2016) ‘Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal’, *Oncology (Switzerland)*, 91(1), pp. 8–17. doi: 10.1159/000447576.
- Lavrik, I. N., Golks, A. and Krammer, P. H. (2005) ‘Caspase: Pharmacological manipulation of cell death’, *Journal of Clinical Investigation*, 115(10), pp. 2665–2672. doi: 10.1172/JCI26252.
- Li, X. *et al.* (2016) ‘Early response to neoadjuvant chemotherapy can help predict long-term survival in patients with cervical cancer’, *Oncotarget*, 7(52), pp. 87485–87495. doi: 10.18632/oncotarget.11460.
- Limpens, M. (2018) ‘Kanker’, *PodoPost*, 31(2), pp. 5–5. doi: 10.1007/s12480-018-0030-x.
- Lindstr, A. (2010) *Prognostic factors for squamous cell cervical cancer*, *Oncology*.
- Ma, S. *et al.* (2019) ‘Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials’, *Gynecologic Oncology*, 154(1), pp. 246–252. doi: 10.1016/j.ygyno.2019.04.013.
- Mabuchi, S. *et al.* (2012) ‘Comparison of the prognoses of figo stage i to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy’, *International Journal of Gynecological Cancer*, 22(8), pp. 1389–1397. doi: 10.1097/IGC.0b013e31826b5d9b.
- Mantovani, F. and Banks, L. (2001) ‘The Human Papillomavirus E6 protein and its contribution to malignant progression’, *Oncogene*, 20(54), pp. 7874–7887. doi: 10.1038/sj.onc.1204869.
- Marin, F. *et al.* (2014) ‘Types of radical hysterectomies : From Thoma Ionescu and Wertheim to present day’, *Journal of medicine and life*, 7(2), pp. 172–176.
- Matsuo, K. *et al.* (2018) ‘Association of tumor differentiation grade and survival of women with

squamous cell carcinoma of the uterine cervix', *Journal of Gynecologic Oncology*, 29(6), pp. 1–12. doi: 10.3802/jgo.2018.29.e91.

- McIlwain, D. R., Berger, T. and Mak, T. W. (2015) 'Caspase functions in cell death and disease', *Cold Spring Harbor Perspectives in Biology*, 7(4), p. 8656. doi: 10.1101/cshperspect.a026716.
- Morshed, K. *et al.* (2014) 'Human Papillomavirus (HPV) - Structure, epidemiology and pathogenesis', *Otolaryngologia Polska*, 68(5), pp. 213–219. doi: 10.1016/j.otpol.2014.06.001.
- Okawa, Y. *et al.* (2008) 'Fatty acid synthase is a novel therapeutic target in multiple myeloma', *British Journal of Haematology*, 141(5), pp. 659–671. doi: 10.1111/j.1365-2141.2008.07114.x.
- Olsson, M. and Zhivotovsky, B. (2011) 'Caspases and cancer', *Cell Death and Differentiation*, 18(9), pp. 1441–1449. doi: 10.1038/cdd.2011.30.
- Panici, P. B. *et al.* (1991) 'Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival', *Cancer*, 67(2), pp. 372–379. doi: 10.1002/1097-0142(19910115)67:2<372::AID-CNCR2820670210>3.0.CO;2-5.
- Prakosa, T., Askandar, B. and Fauziah, D. (2013) 'Ekspresi p53 Mutan dan Caspase 3 sebagai Faktor Prediksi terhadap Operabilitas Kanker Serviks IIB setelah Mendapat Kemoterapi Neoadjuvan', *Indonesian Journal of Cancer*, 7(2), pp. 61–67.
- Putra, A. K., Askandar, B. and Mustokoweni, S. (2015) 'Cleaved caspase-3 sebagai Uji Apoptosis pada Kanker Serviks IIB Tipe Sel Skuamosa yang Mendapat Kemoterapi Neoadjuvan Cisplatin', *Majalah Obstetri & Ginekologi*, 23(1), p. 22. doi: 10.20473/mog.v23i1.2099.
- Putri, R. D. R. (2019) *Hubungan antara ekspresi p53 mutan dan respon kemoterapi neoadjuvan pada kanker serviks stadium IB2 dan IIA2*. Available at: <http://repositorio.unan.edu.ni/2986/1/5624.pdf>.
- R., H. (2014) 'Novel Anticancer Agent for Chemoresistant Cancer Cells that are Caspase-3 Deficient.', *J Mol Biol & Mol Imaging.*, 1(3), p. 8.

- Riemer, A. B. *et al.* (2010) 'A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers', *Journal of Biological Chemistry*, 285(38), pp. 29608–29622. doi: 10.1074/jbc.M110.126722.
- Rydzewska, L. *et al.* (2012) 'Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer', *Cochrane Database of Systematic Reviews*, 2012(12). doi: 10.1002/14651858.CD007406.pub3.
- Shi, X. J. *et al.* (2016) 'Structurally novel steroidal spirooxindole by241 potently inhibits tumor growth mainly through ROS-mediated mechanisms', *Scientific Reports*, 6(February), pp. 1–14. doi: 10.1038/srep31607.
- Stoler, M. *et al.* (2014) 'Squamous Cell Tumours and Precursors', *World Health Organization Classification of Tumours of Female Reproductive Organs*, 4(IARC Lyon, France), pp. 172–182.
- Sugiyama, T. *et al.* (1999) 'Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer', *British Journal of Cancer*, 81(1), pp. 95–98. doi: 10.1038/sj.bjc.6690656.
- Sultana, H. *et al.* (2003) 'Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer', *Annals of Oncology*, 14(2), pp. 214–219. doi: 10.1093/annonc/mdg071.
- Tresnasari, K. (2018) *Hubungan negatif antara ekspresi caspase -3 dengan beberapa faktor klinikopatologi pada karsinoma sel skuamosa invasif serviks uteri.*
- Wei, J. (2015) 'Pathology of Cervical Carcinoma'.
- Wentzensen, N. and Von Knebel Doeberitz, M. (2007) 'Biomarkers in cervical cancer screening', *Disease Markers*, 23(4), pp. 315–330. doi: 10.1155/2007/678793.
- Xia, L. and Xue, X. Z. (2012) 'Immunohistochemical study of NF- κ B p65, c-IAP2 and caspase-3 expression in cervical cancer', *Oncology Letters*, 3(4), pp. 839–844. doi: 10.3892/ol.2012.564.
- Yang, L. *et al.* (2015) 'Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant



UNIVERSITAS
GADJAH MADA

**HUBUNGAN ANTARA EKSPRESI PROTEIN CASPASE 3 DENGAN OPERABILITAS KANKER SERVIKS
STADIUM IIA2 DAN IIB**

POST KEMOTERAPI NEOADJUVAN DI RSUP DR SARDJITO YOGYAKARTA

ERIKA KUSUMAWARDANI, Dr. dr. Ardhanu Kusumanto, Sp.OG(K); Dr. dr. Diah Rumekti Hadiati Sp.OG(K), M.Sc

Universitas Gadjah Mada, 2021 | Diunduh dari <http://etd.repository.ugm.ac.id/>

chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for stage IB2-IIB cervical cancer', *International Journal of Clinical and Experimental Medicine*, 8(8), pp. 13690–13698.

Yang, S.-H. *et al.* (2014) 'Human papillomavirus 18 as a poor prognostic factor in stage I-IIA cervical cancer following primary surgical treatment', *Obstetrics & Gynecology Science*, 57(6), p. 492. doi: 10.5468/ogs.2014.57.6.492.